Recent Developments: Initiated Phase 3 trials for orforglipron, aiming to provide an oral alternative to injectable GLP-1 drugs
however, comparing side by side the outcomes with regard to these end points in the three cardiovascular outcome studies with SGLT2 inhibitors (EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58) and performing meta-analysis, it is clear that there is benefit across the class (Figures 3 and 4)
Tirzepatide: Side effects and safety Tirzepatide can sometimes cause some uncomfortable side effects, and digestive issues like nausea, diarrhea, vomiting, constipation, or stomach discomfort are the most common
Both brand-name medications are recommended as treatment options to lower blood sugar levels in adults with type 2 diabetes mellitus (T2DM) according to guidelines from the American Diabetes Association